|
Fig. 6 Jadomycin B did not deplete overall T cell numbers but may impact a subset of T cells. Adult female Balb/C mice were injected with 100 000 4T1 cells into the fourth mammary fat pad on day 0, followed by jadomycin B (Jad B) treatment (12 mg/kg every 12 h) from day 6 to 15 after tumor cell implantation. On day 16, animals were euthanized for T cell immunological analysis of the primary tumor, draining lymph nodes and spleen. The frequency of CD4+ TCRβ+ T cells (A), immune-activated CD69+ CD4+ T cells (B), CD8+ TCRβ+ T cells, (C) and immune-activated CD69+ CD8+ T cells (D) in the spleen, draining lymph nodes, and primary tumors were measured. The data are shown as mean ± SEM (n = 8). *P ≤ 0.05 indicates significant difference from vehicle control by unpaired t-test.